Analyst Serge Belanger from Needham maintained a Buy rating on Liquidia Technologies and keeping the price target at $36.00.
Meet Your ETF AI Analyst
- Discover how TipRanks' ETF AI Analyst can help you make smarter investment decisions
- Explore ETFs TipRanks' users love and see what insights the ETF AI Analyst reveals about the ones you follow.
Serge Belanger has given his Buy rating due to a combination of factors that highlight Liquidia Technologies’ strong market performance and potential for growth. The company reported impressive sales figures for Yutrepia in the third quarter of 2025, with revenues reaching $51.7 million, a significant increase from the previous quarter and well above market expectations. This robust performance has allowed Liquidia to achieve its first profitable quarter, marking a significant milestone for the company.
Additionally, the rapid adoption of Yutrepia, with over 2,000 unique prescriptions written by more than 600 prescribers, demonstrates strong market acceptance and demand. While there is some uncertainty regarding an upcoming patent litigation decision, the overall outlook remains positive. The anticipated positive market reaction to these results further supports the Buy rating, reflecting confidence in Liquidia’s strategic positioning and future prospects.
In another report released on October 30, H.C. Wainwright also reiterated a Buy rating on the stock with a $35.00 price target.